Shopping Cart
Remove All
Your shopping cart is currently empty
Tigatuzumab
😃Good
Catalog No. T76793Cas No. 918127-53-4
Alias TRA-8, TRA8, CS-1008, CS1008, Anti-Human TRAIL-R2 Recombinant Antibody
Tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5 (DR5), is a TRAIL-R2 agonist with antitumor activity that induces apoptosis in cancer cells, and can be used to study pancreatic cancer.
Tigatuzumab
Tigatuzumab
😃Good
Catalog No. T76793Alias TRA-8, TRA8, CS-1008, CS1008, Anti-Human TRAIL-R2 Recombinant AntibodyCas No. 918127-53-4
Tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5 (DR5), is a TRAIL-R2 agonist with antitumor activity that induces apoptosis in cancer cells, and can be used to study pancreatic cancer.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | In Stock | In Stock | |
| 5 mg | $589 | In Stock | In Stock | |
| 10 mg | $993 | - | In Stock | |
| 25 mg | $1,470 | - | In Stock | |
| 50 mg | $1,980 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:98.9% (SDS-PAGE); 96.6% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5 (DR5), is a TRAIL-R2 agonist with antitumor activity that induces apoptosis in cancer cells, and can be used to study pancreatic cancer. |
| Targets&IC50 | MIAPaCa2 cells:2.95 μg/mL |
| In vitro | Tigatuzumab showed sensitivity to MIA PaCa-2 cells and BxPC-3 cells with IC50 values of 2.95 μg/mL and 8.21 μg/mL, respectively.[1] Tigatuzumab (3-8 μg/mL; 5 hours) was able to induce apoptosis in cancer cells. [1] |
| In vivo | Tigatuzumab (3 mg/kg; i.v.; once weekly for 4 weeks) was effective in inhibiting tumor growth of human pancreatic cancer MIA PaCa-2-RFP in a xenograft mouse model. [1] |
| Synonyms | TRA-8, TRA8, CS-1008, CS1008, Anti-Human TRAIL-R2 Recombinant Antibody |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TNFRSF10B/TRAILR2/CD262 |
| Molecular Weight | 144.63 kDa |
| Cas No. | 918127-53-4 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Tigatuzumab | purchase Tigatuzumab | Tigatuzumab cost | order Tigatuzumab | Tigatuzumab in vivo | Tigatuzumab in vitro | Tigatuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.